779 patents
Page 6 of 39
Utility
Rna Molecules
27 Jul 23
The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV).
Eric Matthew Bennett, Fernando Martin Diaz, Philip Ralph Dormitzer, Kathrin Ute Jansen, Raquel Munoz-Moreno, Alicia Solorzano Quijano
Filed: 12 Oct 22
Utility
Method of Treatment Using Substituted PYRAZOLO[1,5-A] Pyrimidine Compounds
27 Jul 23
Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenarative disease or Typanosoma cruzi infection in a mammal.
Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
Filed: 9 Sep 22
Utility
Method of Treatment of Inflammatory Bowel Disease Using ANTI-TL1A Antibodies
27 Jul 23
The present invention relates to a method for treating inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an anti-TNF-like ligand 1A (TL1A) antibody in an induction dosing regimen sufficient to improve signs and symptoms of IBD by at least 12 weeks after the start of treatment with the anti-TL1A antibody, said induction dosing regimen comprising a plurality of individual induction doses, wherein the method further comprises administering to the patient a subsequent maintenance dosing regimen after completion of the induction dosing regimen, said maintenance dosing regimen comprising a plurality of individual maintenance doses separated from each other by at least 2 weeks.
Mary Lynn BANIECKI, Mina HASSAN-ZAHRAEE, Kenneth Eugene HUNG, Gang LI, Li XI, Zhan YE
Filed: 23 Jun 21
Utility
Immunogenic glycoprotein conjugates
25 Jul 23
Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
Filed: 20 Apr 20
Utility
N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
25 Jul 23
Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
Filed: 5 Mar 21
Utility
Method for Treating Gefitinib Resistant Cancer
20 Jul 23
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer.
Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
Filed: 17 Aug 22
Utility
Compounds and methods of use
18 Jul 23
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity.
Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
Filed: 22 May 21
Utility
Chemical compounds
18 Jul 23
Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
Filed: 12 Apr 21
Utility
Bicyclic-fused heteroaryl or aryl compounds
18 Jul 23
John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
Filed: 18 Aug 20
Utility
Antibodies specific for CD47, PD-L1, and uses thereof
18 Jul 23
Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies.
Javier Fernando Chaparro Riggers, Shih-Hsun Chen, Sheng Ding, Pawel Kamil Dominik, Shahram Salek-Ardakani, Jessica Lynn Stanfield, Thomas John Van Blarcom
Filed: 14 Dec 20
Utility
Combinations for Treatment of NAFLD/NASH and Related Diseases
13 Jul 23
A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.
Neeta Balkrishan Amin, Arthur James Bergman, Roberto Arnaldo Calle, William Paul Esler, Albert Myung Kim, Jeffrey Allen Pfefferkorn, Patrick Robert Verhoest
Filed: 22 Feb 21
Utility
Pharmaceutical Aqueous Formulation Comprising 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA
13 Jul 23
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution.
James Joseph HUSSEY, Andrew Gilbert BRIGHT
Filed: 30 Nov 22
Utility
PYRROLO[2,3-D]PYRIMIDINE Derivatives
13 Jul 23
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Martin Eugene Dowty, Bimal Kumar Malhotra, Ivan Jordan Samardjiev, Brian Matthew Samas, Joseph Walter Strohbach
Filed: 25 May 21
Utility
Immunogenic Compositions Against Clostridioides (Clostridium) Difficile and Methods Thereof
13 Jul 23
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof.
Annaliesa Sybil Anderson, Alexey Vyacheslavovitch Gribenko, William Carl Gruber, Kathrin Ute Jansen, Lakshmi Khandke, Nicholas Randolph Everard Kitchin, Jody Lawrence, Yahong Peng, Michael William Pride, Christopher Frederick Webber, Sabine Susanne Wellnitz, Zhuobiao Yi
Filed: 17 Jun 21
Utility
RSV F Protein Mutants
13 Jul 23
The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
Filed: 29 Mar 23
Utility
Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
11 Jul 23
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides.
Elvire Gouze, Stéphanie Garcia
Filed: 20 Apr 21
Utility
Formulations of Enzalutamide
6 Jul 23
This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
Filed: 11 Nov 22
Utility
Orally Administered Combinations of Beta Lactam Antibiotics and Avibactam Derivatives for Treating Bacterial Infections
6 Jul 23
Pharmaceutical compositions comprising a β-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed.
Joaquim Trias, Carole Sable, Andrew Nicholls
Filed: 13 Mar 23
Utility
3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors
4 Jul 23
Shelley Allen, Patrick Michael Doerner Barbour, James Francis Blake, Sydney Taylor Blanche, Mark Laurence Boys, Wesley Dewitt Clark, Connor James Cowdrey, Joshua Ryan Dahlke, Alex Andrew Kellum, Ellen Margaret Knapp, David Austin Moreno, Jacob Matthew O'Leary, Li Ren, Faith Elizabeth Witkos, Jennifer Lynn Fulton
Filed: 1 Dec 22
Utility
Treatment of Type 2 Diabetes or Obesity or Overweight with 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL}PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC Acid or a Pharmaceutically Salt Thereof
29 Jun 23
The invention provides a method for treating T2DM, obesity or overweight or for weight management control by administering to an mammal (e.g. a human) in need thereof a pharmaceutical composition twice daily in an oral dosage form, wherein the pharmaceutical composition contains 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-5 [(2S)-oxetan-2-ylmethyl]-1H-benzimidazole carboxylic acid, or a pharmaceutically salt thereof [such as its tris salt].
Kai Teck Lee, Sweta Manthena, Aditi Rao Saxena
Filed: 24 Mar 21